PTH Invesco Dorsey Wright Healthcare Momentum ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 63.34 | Day Range | 62.98 – 63.63 |
| 52-Week Range | 39.36 – 64.10 | Volume | 9.26K |
| Avg Volume | 39.98K | AUM | $271.4M (Aug 26, 2026) |
| Expense Ratio | 0.72% | Yield (TTM) | 2.40% |
| NAV | 62.38 | Premium/Discount | +2.00% indicative |
| Inception | Oct 12, 2006 | Holdings | 55 |
| Issuer | Invesco | Exchange | NASDAQ |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 46137V852 | ISIN | US46137V8524 |
| Management | Not stated in source data | ||
About this ETF
The Invesco Dorsey Wright Healthcare Momentum ETF (PTH) is structured to mirror the performance of the Dorsey Wright Healthcare Technical Leaders Index. This exchange-traded fund typically allocates a minimum of 90% of its total assets to the equities found within this benchmark index. The Index itself is specifically engineered to identify healthcare companies that demonstrate strong "relative strength," which indicates significant momentum. It consists of no fewer than 30 individual securities selected from the broader NASDAQ US Benchmark Index. "Relative strength" refers to the process of evaluating a particular security's performance against other comparable investments within its designated market segment over a specific duration. Both the Fund and its underlying Index are subject to quarterly rebalancing and reconstitution.
Description from the fund data provider · profile as of Aug 26, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +8.51% | +23.26% | +27.62% | +27.88% | +62.54% | +20.64% | +2.63% | +14.90% | +10.79% |
| Total return | +8.50% | +23.25% | +27.61% | +27.87% | +67.50% | +21.88% | +3.26% | +15.25% | +11.06% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.72% | Annual cost of a $10,000 investment | $72.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 58 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Revolution Medicines Inc | RVMD | 5.21% | 66.36K | $14.1M |
| 2 | Roivant Sciences Ltd | ROIV | 5.02% | 367.58K | $13.5M |
| 3 | Guardant Health Inc | GH | 4.81% | 77.36K | $13.0M |
| 4 | Moderna Inc | MRNA | 4.31% | 87.18K | $11.6M |
| 5 | BrightSpring Health Services Inc | BTSG | 3.75% | 170.06K | $10.1M |
| 6 | Axsome Therapeutics Inc | AXSM | 3.68% | 47.68K | $9.9M |
| 7 | 10X Genomics Inc | TXG | 2.87% | 121.08K | $7.7M |
| 8 | Oruka Therapeutics Inc | ORKA | 2.78% | 71.50K | $7.5M |
| 9 | Erasca Inc | ERAS | 2.59% | 408.31K | $7.0M |
| 10 | Liquidia Corp | LQDA | 2.38% | 90.27K | $6.4M |
| 11 | Travere Therapeutics Inc | TVTX | 2.32% | 97.24K | $6.3M |
| 12 | Replimune Group Inc | REPL | 2.26% | 434.05K | $6.1M |
| 13 | Twist Bioscience Corp | TWST | 2.21% | 43.79K | $6.0M |
| 14 | Relay Therapeutics Inc | RLAY | 2.20% | 300.86K | $5.9M |
| 15 | Axogen Inc | AXGN | 2.12% | 122.90K | $5.7M |
| 16 | Spyre Therapeutics Inc | SYRE | 2.06% | 51.58K | $5.6M |
| 17 | Illumina Inc | ILMN | 2.02% | 25.57K | $5.5M |
| 18 | Oscar Health Inc | OSCR | 1.98% | 169.37K | $5.3M |
| 19 | agilon health Inc | AGL | 1.95% | 56.83K | $5.3M |
| 20 | Arrowhead Pharmaceuticals Inc | ARWR | 1.95% | 59.98K | $5.2M |
| 21 | Jazz Pharmaceuticals PLC | JAZZ | 1.77% | 19.20K | $4.8M |
| 22 | Cytokinetics Inc | CYTK | 1.77% | 61.69K | $4.8M |
| 23 | Tango Therapeutics Inc | TNGX | 1.74% | 200.07K | $4.7M |
| 24 | Humana Inc | HUM | 1.73% | 12.25K | $4.7M |
| 25 | Centene Corp | CNC | 1.72% | 72.41K | $4.6M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 2.40% | Paid (last 12 months) | $1.5265 |
| Frequency | Irregular | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Dec 22, 2025 | Last payment | $1.5265 (Dec 26, 2025) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 22, 2025 | Dec 22, 2025 | Dec 26, 2025 | $1.5265 |
| Jun 24, 2024 | Jun 24, 2024 | Jun 28, 2024 | $0.0255 |
| Dec 20, 2013 | Dec 24, 2013 | Dec 31, 2013 | $0.0341 |
| Sep 20, 2013 | Sep 24, 2013 | Sep 30, 2013 | $0.0080 |
| Jun 21, 2013 | Jun 25, 2013 | Jun 28, 2013 | $0.1105 |
| Dec 21, 2012 | Dec 26, 2012 | Dec 31, 2012 | $0.3271 |
| Jun 15, 2012 | Jun 19, 2012 | Jun 29, 2012 | $0.0252 |
| Dec 18, 2009 | Dec 22, 2009 | Dec 31, 2009 | $0.0583 |
| Jun 19, 2009 | Jun 23, 2009 | Jun 30, 2009 | $0.0250 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 25.76% / 26.04% | Sharpe 1Y / 3Y | 2.71 / 0.865 |
| Max drawdown 1Y / 3Y | -11.97% / -27.52% | Sortino 1Y | 4.38 |
| Beta vs S&P 500 (3Y) | 1.00 | Correlation vs S&P 500 (1Y) | 0.473 |
| Downside deviation 1Y | 15.93% | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 9.26K | Average volume | 39.98K |
| AUM | $271.4M | Premium/Discount | +2.00% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | -$2.0M | -0.72% | $273.3M → $271.4M |
| 1 Week | $10.6M | +4.04% | $262.9M → $271.4M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for PTH
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.